Literature DB >> 603230

ABO blood groups and cholera.

D Barua, A S Paguio.   

Abstract

The ABO blood group of 87 bacteriologically proven cases of cholera and 33 bacteriologically negative cholera-like diarrhoea cases was determined. When compared with the normal blood group distribution in the population of the Philippines of the same racial group to which the patients belonged, a relatively larger number of cases were found to occur in individuals of group O and a lesser number in those of group A. A plea is made for further studies on these lines to explain the host susceptibility in cholera and other acute enterotoxigenic diarrhoeas.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 603230     DOI: 10.1080/03014467700002481

Source DB:  PubMed          Journal:  Ann Hum Biol        ISSN: 0301-4460            Impact factor:   1.533


  36 in total

1.  Fucosylation and protein glycosylation create functional receptors for cholera toxin.

Authors:  Amberlyn M Wands; Akiko Fujita; Janet E McCombs; Jakob Cervin; Benjamin Dedic; Andrea C Rodriguez; Nicole Nischan; Michelle R Bond; Marcel Mettlen; David C Trudgian; Andrew Lemoff; Marianne Quiding-Järbrink; Bengt Gustavsson; Catharina Steentoft; Henrik Clausen; Hamid Mirzaei; Susann Teneberg; Ulf Yrlid; Jennifer J Kohler
Journal:  Elife       Date:  2015-10-29       Impact factor: 8.140

Review 2.  Prevention and self-treatment of traveler's diarrhea.

Authors:  David J Diemert
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

3.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

4.  Binding of cholera toxin to pig intestinal mucosa glycosphingolipids: relationship with the ABO blood group system.

Authors:  F R Bennun; G A Roth; C G Monferran; F A Cumar
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

Review 5.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

6.  Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Authors:  D A Sack; C O Tacket; M B Cohen; R B Sack; G A Losonsky; J Shimko; J P Nataro; R Edelman; M M Levine; R A Giannella; G Schiff; D Lang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  Natural selection in a bangladeshi population from the cholera-endemic ganges river delta.

Authors:  Elinor K Karlsson; Jason B Harris; Shervin Tabrizi; Atiqur Rahman; Ilya Shlyakhter; Nick Patterson; Colm O'Dushlaine; Stephen F Schaffner; Sameer Gupta; Fahima Chowdhury; Alaullah Sheikh; Ok Sarah Shin; Crystal Ellis; Christine E Becker; Lynda M Stuart; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri; Pardis C Sabeti; Regina C Larocque
Journal:  Sci Transl Med       Date:  2013-07-03       Impact factor: 17.956

8.  Recurrent bacteriuria and primary biliary cirrhosis: ABO blood group, P1 blood group, and secretor status.

Authors:  I J Rosenstein; G R Hazlehurst; A K Burroughs; O Epstein; S Sherlock; W Brumfitt
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

9.  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Authors:  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Authors:  Pardeep Kumar; F Matthew Kuhlmann; Subhra Chakraborty; A Louis Bourgeois; Jennifer Foulke-Abel; Brunda Tumala; Tim J Vickers; David A Sack; Barbara DeNearing; Clayton D Harro; W Shea Wright; Jeffrey C Gildersleeve; Matthew A Ciorba; Srikanth Santhanam; Chad K Porter; Ramiro L Gutierrez; Michael G Prouty; Mark S Riddle; Alexander Polino; Alaullah Sheikh; Mark Donowitz; James M Fleckenstein
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.